Connect with us

Finance

RIV Capital Reports Financial Results for the Third Quarter Ended September 30, 2024

Published

on

RIV Capital Reports Financial Results for the Third Quarter Ended September 30, 2024

Adjusted EBITDA1 loss improves; net loss primarily driven by non-cash pre-tax impairment charge on intangible assets

Ended the quarter with $50.7 million of cash to support growth initiatives in New York and Florida

TORONTO, Nov. 29, 2024 /PRNewswire/ – RIV Capital Inc. (“RIV Capital” or the “Company“) (CSE: RIV) (OTC: CNPOF), a firm dedicated to developing a leading multi-state platform with a strong portfolio of cannabis brands focused on key strategic markets in the United States (“U.S.“), today released its financial results for the third quarter ended September 30, 2024 (“Q3 2024“). All financial information in this press release is reported in U.S. dollars unless otherwise indicated.

“Since the launch of adult-use sales in New York this year, we have achieved significant growth, driven by our ongoing enhancements to customer retail experiences and commitment to delivering exceptional customer service,” said Dave Vautrin, Chief Retail Officer and Interim Chief Executive Officer of RIV Capital. “With our operations scaling as patient and consumer demand continues to build, we experienced significant acceleration in the third quarter results, demonstrated by our record net revenue of $4.9 million. We now proudly operate three co-located adult-use and medical retail dispensaries, plus an additional medical-only location, across our footprint, and customer response has been great, with especially strong enthusiasm following the launch of the highly popular MOODS brand by FLUENT into the New York market.”

Mr. Vautrin added, “As we continue to improve our retail network, we’re also scaling our wholesale operations, with a growing pipeline of approximately 60 retailers. With the recent strategic distribution agreement with Nabis, we’re well-positioned to support this rapid growth across the state. This momentum has continued into the fourth quarter.”

Advertisement

Mr. Vautrin concluded, “Since announcing the proposed Business Combination with Cansortium, we’ve identified and captured substantial synergies, and our joint integration efforts are progressing smoothly. With Cansortium, we’re poised to complete this transaction on a solid foundation and positioned to quickly capitalize on the combined expertise and experience of our teams in some of the most dynamic markets in the cannabis industry.”

1

Adjusted EBITDA is a non-IFRS financial measure that does not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies. A reconciliation of net loss to Adjusted EBITDA is provided in the table “Supplemental Information – Non-IFRS Financial Measures” below.

Regulatory Update

New York State continues to undertake efforts to combat illicit market activities, which the Company believes will positively impact the ability of the legal market to establish a stronger and safer footprint. The Company continues to work closely with the Office of Cannabis Management (“OCM“) and foster its strong relationship with New York stakeholders. At the federal level, the Company continues to monitor developments regarding the rescheduling of cannabis from a Schedule I to a Schedule III substance under the Controlled Substances Act (the “CSA“), as rescheduling is anticipated to lead to the removal of 280E taxes and provide support for further potential federal reform. Additionally, this change has the potential to expand institutional access to invest in the cannabis sector and accelerate opportunities for research into the medical benefits of cannabis.

Advertisement

Business Combination Update

The Company anticipates being in a position to complete the previously announced business combination (the “Business Combination“) with Cansortium Inc. (CSE: TIUM.U) (OTCQB: CNTMF) (“Cansortium“), a vertically integrated, multi-state cannabis company operating under the FLUENT™ brand, in the coming weeks. Closing remains subject to, among other things, the requirement for RIV Capital to maintain a certain minimum cash balance as of a specified date prior to closing, and the satisfaction of certain other closing conditions customary in transactions of this nature, all of which are expected to be completed during this quarter. Further details regarding the Business Combination, including the principal closing conditions and the anticipated benefits for RIV Shareholders, can be found in RIV Capital’s management information circular dated July 12, 2024 in respect of the RIV Meeting (the “Circular“) and in the joint press release issued by RIV Capital and Cansortium on May 30, 2024, both of which can be found under RIV Capital’s SEDAR+ profile at www.sedarplus.ca.

Financial Results for the Third Quarter Ended September 30, 2024

The following is a summary of the Company’s unaudited financial results for the three and nine months ended September 30, 2024, and 2023. As previously announced, the Company has changed its fiscal year end from March 31 to December 31. Accordingly, the comparative period presented for the nine months ended September 30, 2023, had not previously been reported in historical unaudited condensed interim consolidated financial statements published by the Company. Further details regarding the change in fiscal year end, including the length and ending dates of the Company’s financial reporting periods, are available in the Company’s Notice of Change in Year End prepared in accordance with Section 4.8 of National Instrument 48-102 and filed on the Company’s SEDAR+ profile at www.sedarplus.ca.

Unless otherwise indicated, all financial highlights summarized in tables in this press release are presented in thousands of dollars, except share and per share amounts. All references to “$” are to United States dollars.

Advertisement

Summary Operating Results

Three months ended

Sep. 30, 2024

(unaudited)

Three months ended

Advertisement

Sep. 30, 2023

(unaudited)

Nine months
ended

Sep. 30, 2024

(unaudited)

Advertisement

Nine months
ended

Sep. 30, 2023

(unaudited)

Revenue, net

$ 4,859

Advertisement

$ 1,697

$ 10,786

$ 5,211

Cost of goods sold

5,737

Advertisement

1,851

12,571

5,038

Gross profit excluding fair value items

(878)

Advertisement

(154)

(1,785)

173

Unrealized gain (loss) on changes in fair value of biological assets

(520)

Advertisement

214

(598)

493

Realized fair value amounts included in inventory sold

238

Advertisement

(9)

271

(10)

Gross profit

(1,160)

Advertisement

51

(2,112)

656

Selling, general, and administrative expenses

4,583

Advertisement

4,804

16,613

15,442

Impairment of intangible assets

67,372

Advertisement

67,372

Operating loss

(73,115)

Advertisement

(4,753)

(86,097)

(14,786)

Other loss

(3,832)

Advertisement

(3,785)

(8,348)

(27,511)

Loss before taxes

(76,947)

Advertisement

(8,538)

(94,445)

(42,297)

Income tax recovery

(13,588)

Advertisement

(1,152)

(17,816)

(2,199)

Net loss

$ (63,359)

Advertisement

$ (7,386)

$ (76,629)

$ (40,098)

Other comprehensive income (loss)

(1,332)

Advertisement

732

(1,347)

(994)

Total comprehensive loss

$ (64,691)

Advertisement

$ (6,654)

$ (77,976)

$ (41,092)

Net loss per share – basic

$ (0.46)

Advertisement

$ (0.05)

$ (0.56)

$ (0.28)

Net loss per share – diluted

$ (0.46)

Advertisement

$ (0.05)

$ (0.56)

$ (0.28)

 

Supplemental Information – Non-IFRS Financial Measures(1)

Advertisement

Three months

 ended

Sep. 30, 2024

Three months

 ended

Advertisement

Sep. 30, 2023

Nine months

 ended

Sep. 30, 2024

Nine months

Advertisement

 ended

Sep. 30, 2023

Net loss

$ (63,359)

$ (7,386)

Advertisement

$ (76,629)

$ (40,098)

Income tax recovery

(13,588)

(1,152)

Advertisement

(17,816)

(2,199)

Accretion and interest expense, net

3,608

2,610

Advertisement

10,030

7,595

Depreciation and amortization(2)

1,629

692

Advertisement

3,585

2,103

EBITDA

$ (71,710)

$ (5,236)

Advertisement

$ (80,830)

$ (32,599)

Impairment of intangible assets

67,372

Advertisement

67,372

Fair value items in inventory and biological assets

332

(115)

Advertisement

431

(380)

Non-operating expenses (income) (3)

94

202

Advertisement

(1,931)

2,835

Other non-recurring expenses (income)(4)

675

181

Advertisement

4,143

16,558

Adjusted EBITDA

$ (3,237)

$ (4,968)

Advertisement

$ (10,815)

$ (13,586)

(1)

EBITDA and Adjusted EBITDA are non-IFRS financial measures that do not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies.

(2)

Advertisement

Depreciation and amortization includes expenses recognized through both cost of goods sold and selling, general, and administrative expenses.

(3)

Non-operating expenses (income) include foreign exchange, share of loss from associates, impairment of associates, and net change in fair value of financial assets at FVTPL.

(4)

Other non-recurring expenses (income) include litigation settlement expenses, M&A transaction costs, severance, and gain or loss on disposal of fixed assets.

Advertisement

 

Summary Cash Flows and Financial Position Data

Nine months ended

Sep. 30, 2024

(unaudited)

Advertisement

Nine months ended

Sep. 30, 2023

(unaudited)

Net cash flows used in operating activities

$ (9,293)

Advertisement

$ (29,574)

Net cash flows used in investing activities

(19,665)

(5,322)

Net cash flows used in financing activities

Advertisement

(2,033)

(5,717)

Net decrease in cash

$ (30,991)

$ (40,613)

Advertisement

Effect of foreign exchange rate movements on cash held

(195)

8

Cash, beginning of fiscal period

81,887

Advertisement

125,601

Cash, end of fiscal period

$ 50,701

$ 84,996

As at

Advertisement

Sep. 30, 2024

(unaudited)

As at

Dec. 31, 2023

(unaudited)

Advertisement

Current assets

$ 61,928

$ 98,246

Non-current assets

62,980

Advertisement

120,831

Total assets

$ 124,908

$ 219,077

Current liabilities

Advertisement

$ 11,831

$ 19,603

Non-current liabilities

148,920

157,353

Advertisement

Total liabilities

$ 160,751

$ 176,956

Total shareholders’ equity

$ (35,843)

Advertisement

$ 42,121

 

  • Net revenue was $4.9 million for Q3 2024, compared to $1.7 million for the three months ended September 30, 2023 (“CQ3 2023“), representing an increase of 28% quarter-over-quarter and 186% year-over-year. Retail revenue of $3.4 million was generated from Etain LLC’s co-located adult-use and medical retail dispensaries in White Plains, Kingston, and Manhattan, and its medical retail dispensary in Syracuse, compared to $1.5 million in CQ3 2023 from medical-only retail operations. The financial results for Q3 2024 include only a few weeks of revenue contribution from adult-use retail sales in Kingston and Manhattan, as these stores did not begin selling adult-use products until mid-September. Wholesale revenue of $1.6 million was generated from sales of internally-produced adult-use and medical cannabis products to other adult-use or medical dispensaries in New York, as well as sales of bulk flower to other license holders in the New York adult-use market, compared to $0.3 million in CQ3 2023. The change in net revenue between the two periods reflects the impact of the early stages of the Company’s transition to serve the New York adult-use market.

  • Cost of goods sold (which excludes unrealized fair value changes included in biological assets and realized fair value changes included in inventory sold) was $5.7 million for Q3 2024, compared to $1.9 million for CQ3 2023. The increase in cost of goods sold relative to the comparative period was attributable to the greater revenue base for the current period, an increase in the Company’s inventory reserve, and a lower volume of finished goods production. The increase in inventory reserve recognized during the current quarter resulted in the negative gross profit identified below.

  • The Company reported an unrealized loss on changes in fair value of biological assets of $0.5 million and realized fair value amounts included in inventory sold of $0.2 million for Q3 2024, compared to an unrealized gain on biological assets of $0.2 million and a nominal fair value realization included in inventory sold for CQ3 2023. The unrealized loss in the current period was primarily attributable to a reduction in the estimated selling price for bulk flower used in the fair value analysis.

  • The Company reported a gross profit of $(1.2) million for Q3 2024, compared to $0.1 million for CQ3 2023.

  • Selling, general, and administrative (“SG&A“) expenses were $4.6 million for Q3 2024, down from $4.8 million in CQ3 2023. While the scope of the Company’s operations has increased since the comparative period, the Company has sought to achieve greater efficiencies in its SG&A cost profile, with year-over-year decreases in personnel, non-M&A advisory, and insurance expenses.

  • The Company reported an impairment of intangible assets of $67.4 million for Q3 2024, compared to no impairment in CQ3 2023. The impairment charge related to the cannabis license rights and brands acquired in the acquisition of Etain in April 2022, and reflect lower anticipated operating profits for the New York market compared to the last impairment testing date. The impairment expense is a non-cash item in the current period and reduces the carrying value of the Company’s intangible assets on its unaudited condensed interim consolidated statements of financial position to $10.9 million.

  • Other loss was $3.8 million for Q3 2024, compared to $3.8 million in CQ3 2023. Consistent with prior periods, the most significant factor impacting other loss was non-cash accretion and interest expense.

  • The Company reported a net loss of $63.4 million, and a basic and diluted net loss per share of $0.46, for Q3 2024, compared to a net loss of $7.4 million, and a basic and diluted net loss per share of $0.05, for CQ3 2023. The most significant factor impacting net loss in the current period was the $67.4 million non-cash pre-tax impairment expense described above.

  • Other comprehensive loss was $1.3 million for Q3 2024, compared to other comprehensive income of $0.7 million for CQ3 2023.

  • Total comprehensive loss was $64.7 million for Q3 2024, compared to a total comprehensive loss of $6.7 million for CQ3 2023.|

  • The Company reported an Adjusted EBITDA (as defined below) loss of $3.2 million for Q3 2024, compared to an Adjusted EBITDA loss of $5.0 million for CQ3 2023. Adjusted EBITDA is a non-IFRS financial measure that management believes provides meaningful insight into the Company’s operational performance. While not directly comparable to measures used by other companies, Adjusted EBITDA offers a view of the Company from management’s perspective and is intended to complement IFRS measures in understanding the Company’s financial results. A reconciliation of net loss to EBITDA and Adjusted EBITDA is provided in the table “Supplemental Information – Non-IFRS Financial Measures” above.

This press release should be read in conjunction with the Company’s unaudited condensed interim consolidated financial statements and management’s discussion and analysis for the three and nine months ended September 30, 2024 and 2023, which are available under the Company’s profile on SEDAR+ at www.sedarplus.com and on the Company’s website at www.rivcapital.com/investors.

About RIV Capital

RIV Capital is a firm dedicated to developing a leading multi-state platform with a strong portfolio of cannabis brands focused on key strategic markets in the U.S. Backed by in-house expertise and cannabis domain knowledge, RIV Capital aims to grow its own brands and partner with established U.S. cannabis operators and brands to bring them to new markets and build market share. RIV Capital established the foundational building blocks of its active U.S. strategy with its previously announced acquisition of Etain. Through its strategic relationship with The Hawthorne Collective, Inc. (“The Hawthorne Collective”), a subsidiary of The ScottsMiracle-Gro Company (“ScottsMiracle-Gro”), RIV Capital is The Hawthorne Collective’s preferred vehicle for cannabis-related investments not under the purview of other ScottsMiracle-Gro subsidiaries.

Advertisement

Non-IFRS Measures

This press release includes references to “EBITDA” and “Adjusted EBITDA” (each, as defined below), which are non-IFRS (as defined below) financial measures. The Company believes that these non-IFRS financial measures, in addition to conventional measures prepared in accordance with International Financial Reporting Standards (“IFRS“), provide information that is helpful to understand the results of operations and financial condition of the Company. The objective is to present readers with a view of the Company from management’s perspective by interpreting the material trends and activities that affect the operating results, liquidity, and financial position of the Company. These non-IFRS measures are not recognized under IFRS and, accordingly, readers are cautioned that these measures should not be construed as alternatives to net income (loss) determined in accordance with IFRS. These non-IFRS measures are not necessarily comparable to similarly-titled measures used by other companies.

The Company defines “EBITDA” as net income (loss) under IFRS, adjusted for accretion and net interest expense (income), income tax expense (recovery), and depreciation and amortization. The Company defines “Adjusted EBITDA” as EBITDA, adjusted for impairment on intangible assets, fair value losses (gains) in inventory and biological assets, non-operating expenses (income), and other non-recurring expenses (income), as determined by management. See “Financial Results for the Third Quarter Ended September 30, 2024 – Supplemental Information – Non-IFRS Financial Measures” above. The terms EBITDA and Adjusted EBITDA do not have any standardized meaning according to IFRS and therefore may not be comparable to similar measures presented by other companies.

Forward Looking Statements

This press release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “enables”, “intends”, “anticipates” or “does not anticipate”, “potential”, “seeks” or “believes”, or variations of such words and phrases, or state that certain actions, events or results “may”, “can”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Cansortium, RIV Capital or their respective subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this press release. Examples of such statements include, but are not limited to, statements regarding: RIV Capital’s expectations regarding rapid growth as a result of the strategic distribution agreement with Nabis; RIV Capital’s beliefs regarding the legal market for cannabis in New York State;  RIV Capital’s expectations regarding its relationship with the OCM; RIV Capital’s continued monitoring of and expectations regarding the rescheduling of cannabis under the CSA; the timing and completion of the proposed Business Combination between RIV Capital and Cansortium; the anticipated benefits and synergies created by ongoing integration activities and the impact such activities will have on the financial and operating performance of RIV Capital, Cansortium, and the combined company, including, but not limited to, operational efficiencies, expanded product and brand portfolios, and improvements to the in-store customer experience; expectations regarding the ability of RIV Capital, Cansortium, or the combined company’s ability to achieve or take advantage of such anticipated benefits; the estimated growth opportunities as a result of the Business Combination and ongoing integration activities, including the combined company’s total addressable market at maturity; RIV Capital’s dedication to developing a leading multi-state platform with a strong portfolio of cannabis brands; expectations regarding the U.S. cannabis market; and expectations for other economic, business and/or competitive factors. 

Advertisement

Investors are cautioned that forward-looking information is not based on historical fact but instead reflects management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although RIV Capital believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of RIV Capital or its portfolio companies.

Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information include: the prompt and effective integration of Cansortium’s and RIV Capital’s businesses and the ability to achieve the anticipated synergies contemplated by the Business Combination and ongoing integration activities; the diversion of management time on issues related to the Business Combination transaction; expectations regarding future investment, growth and expansion of Cansortium’s and RIV Capital’s operations; regulatory and licensing risks; Cansortium’s and RIV Capital’s reliance on licenses issued by state authorities; future levels of revenues and the impact of increasing levels of competition; changes in laws, regulations and guidelines and Cansortium’s and RIV Capital’s compliance with such laws, regulations and guidelines; the timing and manner of the legalization of cannabis in the United States; business strategies, growth opportunities and expected investment; the potential effects of judicial, regulatory or other proceedings, litigation or threatened litigation or proceedings, or reviews or investigations, on Cansortium’s and RIV Capital’s business, financial condition, results of operations and cash flows; risks associated with divestment and restructuring; the anticipated effects of actions of third parties such as competitors, activist investors or federal, state, provincial, territorial or local regulatory authorities, self-regulatory organizations, plaintiffs in litigation or persons threatening litigation; consumer demand for cannabis; risks related to stock exchange restrictions; risks related to the protection and enforcement of Cansortium’s and RIV Capital’s intellectual property rights; future levels of capital, environmental or maintenance expenditures, general and administrative and other expenses; changes in general economic, business and political conditions, including changes in the financial and stock markets; inflation risks; risks relating to the economic impacts caused by the ongoing conflicts in Europe and the Middle East; risks relating to anti-money laundering laws; compliance with extensive government regulation and the interpretation of various laws, regulations, and policies; public opinion and perception of the cannabis industry; and such other risks contained in the public filings of Cansortium filed with Canadian securities regulators and available under Cansortium’s profile on SEDAR+ at www.sedarplus.ca and in the public filings of RIV Capital filed with Canadian securities regulators and available under RIV Capital’s profile on SEDAR+ at www.sedarplus.ca, including RIV Capital’s annual information form for the year ended March 31, 2023, annual management’s discussion and analysis for the nine-month period ended December 31, 2023, and Circular dated July 12, 2024 under the heading “Risk Factors”.

Cansortium and RIV Capital, through several of their respective subsidiaries, are directly involved in the manufacture, possession, use, sale, and distribution of cannabis in the adult-use and medical cannabis marketplace in the U.S. Local state laws where Cansortium and RIV Capital operate permit such activities, however, investors should note that there are significant legal restrictions and regulations that govern the cannabis industry in the U.S. Cannabis remains a Schedule I drug under the U.S. Controlled Substances Act, making it illegal under federal law in the U.S. to, among other things, cultivate, distribute, or possess cannabis in the U.S. Financial transactions involving proceeds generated by, or intended to promote, cannabis-related business activities in the U.S. may form the basis for prosecution under applicable U.S. federal money laundering legislation.

While the approach to enforcement of such laws by the federal government in the U.S. has trended toward non-enforcement against individuals and businesses that comply with adult- use and medical cannabis programs in states where such programs are legal, strict compliance with state laws with respect to cannabis will neither absolve Cansortium and RIV Capital of liability under U.S. federal law, nor will it provide a defense to any federal proceeding which may be brought against Cansortium or RIV Capital. The enforcement of federal laws in the U.S. is a significant risk to the business of Cansortium and RIV Capital and any proceedings brought against Cansortium or RIV Capital thereunder may adversely affect operations and financial performance.

Should one or more of the foregoing risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although Cansortium and RIV Capital have attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The forward-looking information and statements included in this press release are made as of the date of this press release and Cansortium and RIV Capital do not undertake any obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

Advertisement

 

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/riv-capital-reports-financial-results-for-the-third-quarter-ended-september-30-2024-302318700.html

SOURCE RIV Capital Inc.

Finance

Budget crisis is top concern for MPS leader Cassellius | Opinion

Published

on

Budget crisis is top concern for MPS leader Cassellius | Opinion


Before seeking a new referendum MPS needs to rebuild trust in the community through completing state audits, putting in place controls to prevent overspending and routine reports to the public.

For MPS Superintendent Brenda Cassellius, who just wrapped up her first year leading Milwaukee’s public school system, her tenure has been punctuated by some very big numbers.

The first is $252 million. That is the amount of new spending voters narrowly approved in an April 2024 referendum to support operations in Wisconsin’s largest school district. Just months later, MPS was rocked by revelations the district was months behind in filing key financial reports to the state, which led to former Superintendent Keith Posley’s resignation.

The second is $1 billion. MPS faces a deferred maintenance backlog exceeding $1 billion. The district’s enrollment has declined 30% over the last 30 years, leaving many schools at less than 50% full. That, in part, is driving a plan to close some schools and to improve others to help lower costs.

Advertisement

The final is $46 million, the deficit MPS was running for the 2024-25 school year, an unexpected shortfall which has led to hundreds of staff layoffs.

Getting the district’s accounting, budgeting and financial reporting back on track has dominated Cassellius’s first year at MPS. In an April 15 interview with the Journal Sentinel’s editorial board, she talked in detail about the challenges putting that into order and progress she sees in restoring transparency into its operations.

State funding and aging buildings create budget nightmares

play

Cassellius says state needs to keep up its share of school funding

In an interview with the Journal Sentinel editorial board, MPS leader Brenda Cassellius says budgets and buildings are her two top worries.

Advertisement

Cassellius said the on-going budget crisis is her top concern. She said the state’s failure to live up to its share of funding is exacerbating MPS’ budget woes. A group of school districts, teachers and parents filed suit against the state Legislature and its Joint Finance Committee claiming the current state funding system is unconstitutional and prevents schools from meeting students’ educational needs.

Funding for special education is especially critical. About 20% of MPS students have disabilities, almost twice the share of the city’s charter schools, and the average of 14% across Wisconsin.

“What’s keeping me up now, you know, is really just the budget crisis we’re in, with not only this year but multiple years going out without additional state aid, we’ve been not getting funding for what our needs are for our students, and particularly our students with special needs,” she said.

Advertisement

Although the state budget increased special education funding to a 42% reimbursement rate, the actual rate has been about 35%. Another component to the budget headache is the age of MPS buildings. The average age is 85 years-old compared to 45 across the nation.

“We have just kicked this can down the curb or kicked it down the street or whatever you call it for too long. And it’s time that we really take on a serious conversation about the conditions of the learning environments in which we send our children,” she said. “Particularly in Milwaukee Public Schools, we serve the most vulnerable children. Children who have language barriers, children who have disabilities, children in high-concentrated poverty.”

What needs to happen before MPS seeks another referendum

play

Voters need to be comfortable MPS has made tough budget decisions

In an interview with Journal Sentinel editorial board, Brenda Cassellius said voters will need to see budget improvements before seeking more spending

Cassellius said MPS will definitely need to go back to voters for a new referendum in the future. In addition to the 2024 measure, voters approved an $87 million plan in 2020.

Advertisement

Before doing that, she said the district first needs to rebuild trust in the community through completing required state audits, putting into place controls to prevent overspending and routine reports to the school board and public about finances.

“I don’t think that the voters are going to want us to bring something forward until they feel comfortable that we have done the cleanup that is necessary,” she said. “And we’ve built the trust that we have the sufficient controls in place.”

In the interim, she’s hoping the state will meet its constitutional responsibility to adequately fund public schools.

“What the public expects is you know where the money is, you’re spending it as close as you can to children, you’re getting good on the promise around art, music, and PE, and the things the public said they wanted to fund,” Cassellius said. “And they want their kids to have so that they have a quality education and an excellent education in Milwaukee Public Schools, and that they had the right amount of staff that they actually need. In the school to be safe and to run a good operation.”

Advertisement

Rebuilding finance staff in wake of $46 million in overspending

play

MPS is rebuilding school finance staff in wake of reporting lapses

In an interview with the Journal Sentinel editorial board April 15, MPS superintendent discusses accountability for district’s financial problems.

The $46 million budget shortfall from the 2024-25 school year started coming into view last fall and was confirmed in mid-January. Cassellius noted that in addition to hiring a new superintendent, MPS also parted ways with its comptroller and CFO.

“We are really rebuilding the personnel and staff of the finance department. That is what’s critical, is having the right people in the right seats doing the work,” she said. “Also critical is making sure that you have the right controls in place. The audit findings found that we did not have proper controls in place and now we have those proper controls in place and when we find things we put new SOPs in place and that is what any business does.”

Advertisement

Identifying that shortfall, though painful, was the result of better accounting.

“Being three years behind in auditing means that you don’t have full sight on your actual revenues and expenditures. And so we have now full sight of our revenues and our expenditures and that’s why we were able to see this new deficit of $46 million,” she said. “And we still continue to work with DPI on those processes to make sure that every month we’re doing monthly to actuals and doing those accounting, reporting that to the board. In a way that is consumable to the public that they can understand.”

Jim Fitzhenry is the Ideas Lab Editor/Director of Community Engagement for the Milwaukee Journal Sentinel. Reach him at jfitzhen@gannett.com or 920-993-7154.

Continue Reading

Finance

Psychological shift unfolds in soft Aussie housing market: ‘Vendors feel pressure’

Published

on

Psychological shift unfolds in soft Aussie housing market: ‘Vendors feel pressure’
Is it becoming a buyers market? (Source: Getty)

Property markets move in cycles, and with interest rates rising and other pressures like high fuel costs, some markets are clearly slowing down. Many first-home buyers who have only ever seen markets going up are conditioned to think that when purchasing, competition is always intense and decisions need to be made quickly.

In those times, buyers often feel they need to act fast, stretch their budget and secure a property at almost any cost. But things have definitely changed.

In a softer market, the dynamic shifts. Properties take longer to sell, competition thins, and it’s the vendors who begin to feel pressure.

RELATED

For buyers who understand how to navigate that change, the balance of power quickly moves in their favour. The opportunity is not simply to buy at a lower price. It is to negotiate from a position of strength.

Advertisement

If that’s you right now, these are the key skills first-home buyers need to take advantage of in softer market conditions.

The most important shift in a soft market is psychological. In a rising market, buyers often feel like they are competing for limited opportunities. In a softer market, the opposite is true. There are more properties available, fewer active buyers and less urgency overall. This gives buyers options.

When buyers understand that they are not competing with multiple parties on every property, their decision-making improves. They are more willing to walk away, compare opportunities and avoid overpaying. Negotiation strength comes from not needing to transact immediately. When that pressure is removed, buyers are able to engage more strategically.

One of the most common mistakes first-home buyers make is continuing to apply strategies that only work in rising markets. Auction urgency is a clear example. In strong markets, auctions often attract multiple bidders and create competitive tension. In softer conditions, properties are more likely to pass in, shifting the process away from a public bidding environment into a private negotiation.

This is where leverage increases.

Advertisement

Private negotiations allow buyers to introduce conditions that protect their position. These may include finance clauses, longer settlement periods or price adjustments based on due diligence. Opportunities that are rarely available in competitive markets become standard in softer ones.

Advertisement
Continue Reading

Finance

Finance Committee approves an average increase of University tuition by 3.6 percent

Published

on

Finance Committee approves an average increase of University tuition by 3.6 percent

The Board of Visitors Finance Committee met Thursday and approved a 3.6 percent average increase in tuition, a 4.8 percent average increase in meal plan costs and a 5 percent increase in the cost of double-room housing for the 2026-27 school year. The approval was unanimous amongst Board members, though some expressed resistance to the increases before voting in favor of them. 

The Committee heard from Jennifer Wagner Davis, executive vice president and chief operating officer, and Donna Price Henry, chancellor of the College at Wise, about reasons for the raise in tuition and rates. According to Davis and Henry, salary increases for professors and legislation passed by the General Assembly contribute to tuition and rates increases.  

The Finance Committee, chaired by Vice Rector Victoria Harker, is responsible for the University’s financial affairs and business operations, and the Committee manages the budget, tuition and student fees. 

Changes in tuition vary between schools, with the School of Law seeing at most a 5.1 percent increase, the School of Engineering & Applied Science seeing at most a 3.2 percent increase and the College of Arts and Sciences seeing at most a 3.1 percent increase in tuition for the 2026-27 school year. 

For the 2026-27 school year at the College at Wise, the Committee also unanimously approved a 2.5 percent average increase in tuition, a 3.8 percent increase in meal plans and a 2 percent increase in the cost of housing.

Advertisement

Last year, the Committee approved a 3 percent average increase in tuition, a 5.5 percent increase in meal plans and a 5.5 percent increase in the cost of housing for the University.

Davis cited increased costs as the primary reason for the approved increase in tuition. She said that the budget that could be passed by the General Assembly for June 30, 2027 through June 30, 2028 could increase professor salaries — University professors receive raises via this process. Davis said that the Senate and House of Delegates have separate proposals dealing with the pay increases that are currently unresolved, with House Bill 30 raising salaries by 2 percent and Senate Bill 30 raising salaries by 3 percent. 

Davis said every percent increase in faculty salaries costs the University $15 million annually, and the Commonwealth will increase funding to the University by $1-2 million to help pay for that increase. According to Davis, the most common way to stabilize the budgetary imbalance caused by raised salaries is through tuition raises. 

Beyond the increase in salary, Davis cited the minimum wage increase, inflation and Virginia Military Survivors & Dependents Education Program as increased costs to the University. VMSDEP is a program that gives education benefits to spouses and children of disabled veterans or military service members killed, missing in action or taken prisoner. Davis said that the program is “partially unfunded” and could cost the University somewhere between $3.6 to $6 million, depending on how many students qualify for the program.

Davis spoke on other contributing factors to the increase in tuition, specifically collective bargaining — which allows workers to bargain for better wages and working conditions.

Advertisement

“If we look at other institutions or other states that have collective bargaining, [collective bargaining] does put an upward pressure on tuition,” Davis said.

Prior to Thursday’s meeting, the Committee heard the proposal for tuition increases from Davis and Henry April 6 in a Finance Committee tuition workshop with public comment. During the tuition workshop, tuition increases ranged from 3 to 4.5 percent for the University and 2 to 3 percent for the College at Wise. Both increases approved Thursday are within the ranges originally proposed.

Meal plan costs, on average, will be increasing by 4.8 percent in the upcoming academic year. Davis said that the University has been expanding dining options with the opening of the Gaston House and new locations for the Ivy Corridor student housing that is still in progress. She also said that the University has been taking steps to increase the availability of allergen-friendly food options. 

Davis shared that the 5 percent cost increase in housing is due to the expansion of student housing in the Ivy Corridor. Davis also said that there will be 3,000 new units added to the Charlottesville housing market by 2027, of which 780 beds will be for University housing. Davis said that she hopes the Ivy Corridor housing would “free up” the city housing supply by having more students live on Grounds.

Board member Amanda Pillion said she was “concerned” about how tuition increases would harm rural families — she said the constant increases in cost could make a University education out of reach for middle-income Virginians. 

Advertisement

“This is the second governor I’ve served under. Both times I’ve heard affordability, affordability, affordability,” Pillion said. “We need to really be conscious of the fact that … there is a large group of people that [are middle-income] that these increases [in tuition and fees] are really tough for.”

The Committee also approved a renovation for The Park — an 18-acre recreational hub in North Grounds — which will cost $10 million. As part of the renovation, The Park will include a maintenance facility, storm water systems and a maintenance access route. Davis said the renovation will address safety and security issues for the 200 people that use The Park daily. According to Davis, the University will use $2 million of institutional funds and issue $8 million of debt to fund the renovation. 

The Finance Committee will reconvene during the regularly scheduled June Board meetings.

Advertisement
Continue Reading
Advertisement

Trending